Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes of zoledronate and alendronate in Chinese women with osteoporosis
ChiCTR1800015367Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronate and alendronate in osteoporosis (4 arms), sponsored by Tongji Hospital. Primary endpoints: mortality, bone fracture and 3 more. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
zoledronatealendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR1800015367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015367.